IRLA
IRulya Therapeutics Inc.
IRLA | NASDAQ
$32.45
-$0.50 (-1.52%)
Nov 2, 2026, 10:15 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -1.99 | -1.43 | -1.25 | -0.41 | -4.17 | -10.56 |
PEG Ratio | -0.07 | -0.03 | 0.03 | 0.01 | -0.27 | -0.29 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | -4.70 | 2.68 | 0.46 | 0.21 | 3.16 | 4.71 |
P/FCF Ratio | -4.02 | -2.52 | -2.12 | -0.48 | -5.94 | -15.93 |
P/OCF Ratio | -4.05 | -2.54 | -2.14 | -0.48 | -5.96 | -15.95 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | -0.52 | 0.49 | 0.16 | 0 | 0.01 | 0 |
Quick Ratio | 0.53 | 6.05 | 8.09 | 30.55 | 7.85 | 8.11 |
Current Ratio | 0.53 | 6.05 | 8.09 | 30.55 | 7.85 | 8.11 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | -91.58 | n/a | n/a |
Return on Equity | 235.14% | -188.51% | -36.89% | -51.36% | -75.85% | -44.61% |
Return on Assets | -89.80% | -49.64% | -17.42% | -49.72% | -67.51% | -40.56% |
Return on Invested Capital | -73.69% | -53.39% | -20.16% | -51.07% | -75.42% | -45.68% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove IRLA